Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 25, 2022ESC Heart FailureOpen Access

SGLT2i reduced the composite of first hospitalization for heart failure or cardiovascular death compared to placebo (HR 0.76, 95% CI 0.71-0.81).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The study aimed to examine the efficacy and safety outcomes of SGLT2i for the treatment of heart failure, especially in patients with HFpEF.

Do sodium-glucose cotransporter-2 inhibitors reduce the composite of first hospitalization for heart failure or cardiovascular death in patients with heart failure?

Population

23 852 HF patients across 10 studies

Comparison

SGLT2i vs placebo

Design

Meta-analysis of randomized controlled trials

Authors

YCYang CaoPLPengxiao LiYLYi Li

Discussion

Loading...

Member takes

Overview

Supports SGLT2i as foundational HF therapy; extends prior RCT benefits across the full spectrum including HFpEF.

Structured PICO

Do sodium-glucose cotransporter-2 inhibitors reduce the composite of first hospitalization for heart failure or cardiovascular death in patients with heart failure?

P
Population
10 randomized controlled trials pooling 23,852 patients with heart failure (including HFpEF)
I
Intervention
Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
C
Comparator
Placebo
O
Outcome
Composite of first hospitalization for heart failure (HHF) or cardiovascular death (CV death)composite

SGLT2 inhibitors significantly reduce the risk of cardiovascular death and heart failure hospitalizations across the spectrum of heart failure, including HFpEF.

Cite This Study

Cao et al. (2022) studied this question.

synapsesocial.com/papers/6a8a49f5176d2ac34cfbd16ahttps://doi.org/10.1002/ehf2.13905
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with a Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials2022 · 5 citations
  2. 2Effectiveness of SGLT2 inhibitor therapy in treatment of Heart failure: A Meta-Analysis2023
  3. 3Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials2023 · 8 citations
  4. 4Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis2022 · 28 citations
  5. 5SGLT2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Trials and Observational Studies2026